The MAST trial is designed to test whether a single dose of pre-emptive, orally administered EBX-102-02 can protect and restore microbial diversity during transplantation
Phase I EPRAD study of DT-9081 demonstrated a favorable safety profile
The initiative provides clearer regulatory guidance and a defined path from research in space to patient access on Earth
Huwel’s diagnostic solutions leverage open RT-PCR system
The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
Arcellx develops innovative immunotherapies for cancer and other incurable diseases
Sugemalimab, developed using CStone’s OmniRat transgenic platform, is a fully human IgG4 monoclonal antibody designed to minimize immunogenicity and toxicity
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
Subscribe To Our Newsletter & Stay Updated
